Electrochemical heavy-metal sensors achieve trace-level sensitivity, but fouling, organic-matter binding and unvalidated algorithms still block dependable long-term field water monitoring.

Microfluidic continuous-flow manufacturing can turn theranostic liposomes from bespoke laboratory preparations into reproducible, scalable, GMP-ready products fit for clinical trials.

Corona engineering converts nanocarrier surface chemistry into a controllable determinant of circulation time, hepatic escape and tumour delivery.

Glucose-responsive nanogels can autonomously sense hyperglycemia and release insulin proportionally, offering a needle-sparing route toward hypoglycemia-free, self-regulated diabetes care.

Dose-optimized iron oxide nanoparticles may reinforce tomato's antioxidant defenses, offering a promising, low-input route to drought resilience.

Organoid-based screening exposes nano–bio behaviour that two-dimensional culture hides, making theranostic nanomedicine selection patient-specific, heterogeneity-aware and clinically translatable.

Treating light as a programmable reagent lets chemists sculpt nanocrystal shape, size and handedness with spatial, spectral and temporal precision.

This review explains why most nanomedicines fail clinically and outlines integrated biological, manufacturing and regulatory strategies to accelerate patient access.

Integrating diagnostic, therapeutic and regenerative nanotechnologies clarifies which platforms are clinically ready and which translational barriers demand coordinated, standardised research.

Smart nanomaterials unite sensing, targeted therapy and AI-guided monitoring, but standardized safety testing and scalable manufacture must precede clinical adoption.

Integrating clinical, toxicological, ethical, and regulatory evidence, this review shows nanomedicine's benefits depend on safety-by-design, harmonised regulation, and equitable access.

Patient-derived organoids expose subclone-specific nanoparticle delivery that conventional models conceal, redirecting theranostic design toward the cells driving colorectal cancer relapse.